Keros Therapeutics focuses on discovering and developing novel treatments for a wide variety of serious, rare, and life-altering diseases by modulating the transforming growth factor-beta protein superfamily signaling pathway. Its clinical and preclinical pipeline targets conditions such as Duchenne muscular dystrophy, myelodysplastic syndromes, pulmonary arterial hypertension, and other rare neuromuscular, hematologic, and cardiovascular disorders. By targeting specific molecular mechanisms that regulate tissue repair, muscle growth, and red blood cell production, the company aims to address significant unmet medical needs where traditional therapeutic options remain severely limited.